Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.
Advances such as new nontoxic, more effective immunotherapy and improvements that significantly reduce recovery times for complicated surgeries are making cancer treatments less taxing. On the horizon are more ways to give patients the greatest chance of survival while also reducing negative consequences of treatment. Some therapies also will improve the experience, such as chemotherapy consisting of quick subcutaneous injections instead of hours in an infusion chair.
